Graft-versus-host disease: state of the science.
作者信息
Alousi Amin M, Bolaños-Meade Javier, Lee Stephanie J
机构信息
Dept of Stem Cell Transplant and Cellular Therapy, Univeristy of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 423, Houston, TX 77030, USA.
出版信息
Biol Blood Marrow Transplant. 2013 Jan;19(1 Suppl):S102-8. doi: 10.1016/j.bbmt.2012.10.028. Epub 2012 Oct 27.
Abstract
摘要
相似文献
1
Graft-versus-host disease: state of the science.移植物抗宿主病：科学现状
Biol Blood Marrow Transplant. 2013 Jan;19(1 Suppl):S102-8. doi: 10.1016/j.bbmt.2012.10.028. Epub 2012 Oct 27.
2
The impact of HLA-E polymorphisms in graft-versus-host disease following HLA-E matched allogeneic hematopoietic stem cell transplantation.HLA-E基因多态性对HLA-E配型相合的异基因造血干细胞移植后移植物抗宿主病的影响
Iran J Allergy Asthma Immunol. 2012 Mar;11(1):15-21.
3
[Graft-versus-host disease].
Klin Med (Mosk). 1993;71(5):19-23.
4
Protective conditioning for acute graft-versus-host disease.急性移植物抗宿主病的保护性预处理
N Engl J Med. 2005 Dec 22;353(25):2718; author reply 2718. doi: 10.1056/NEJMc052921.
5
Graft-versus-host disease: a surge of developments.移植物抗宿主病：进展激增。
PLoS Med. 2007 Jul;4(7):e198. doi: 10.1371/journal.pmed.0040198.
6
Graft-versus-host disease.
N Engl J Med. 1991 Mar 7;324(10):667-74. doi: 10.1056/NEJM199103073241005.
7
[Graft-versus-host disease].[移植物抗宿主病]
Rev Clin Esp. 1986 Sep;179(4):165-6.
8
Topical armamentarium in the management of acute and chronic graft-versus-host disease.急性和慢性移植物抗宿主病治疗中的局部治疗手段
J Pediatr Oncol Nurs. 1997 Oct;14(4):239-51. doi: 10.1177/104345429701400407.
9
Potential of glycosylation research in graft versus host disease after allogeneic hematopoietic stem cell transplantation.糖基化研究在异基因造血干细胞移植后移植物抗宿主病中的潜力。
Biochim Biophys Acta. 2016 Aug;1860(8):1615-22. doi: 10.1016/j.bbagen.2016.02.015. Epub 2016 Feb 26.
10
Biomarkers for acute and chronic graft-versus-host disease in regulatory T cells.调节性 T 细胞中急性和慢性移植物抗宿主病的生物标志物。
Transpl Immunol. 2012 Dec;27(4):179-83. doi: 10.1016/j.trim.2012.07.003. Epub 2012 Aug 4.
引用本文的文献
1
New therapeutic targets and biomarkers for acute graft-versus-host disease (GVHD).急性移植物抗宿主病（GVHD）的新治疗靶点和生物标志物。
Expert Opin Ther Targets. 2021 Sep;25(9):761-771. doi: 10.1080/14728222.2021.1992383. Epub 2021 Nov 1.
2
Impact of Toxicity on Survival for Older Adult Patients after CD34 Selected Allogeneic Hematopoietic Stem Cell Transplantation.毒性对 CD34 分选的异基因造血干细胞移植后老年患者生存的影响。
Biol Blood Marrow Transplant. 2018 Jan;24(1):142-149. doi: 10.1016/j.bbmt.2017.08.040. Epub 2017 Sep 22.
3
Effects of Late Toxicities on Outcomes in Long-Term Survivors of Ex-Vivo CD34-Selected Allogeneic Hematopoietic Cell Transplantation.体外 CD34 选择的异基因造血细胞移植后晚期毒性对长期生存者结局的影响。
Biol Blood Marrow Transplant. 2018 Jan;24(1):133-141. doi: 10.1016/j.bbmt.2017.08.033. Epub 2017 Sep 1.
4
Conditioning with Fludarabine-Busulfan versus Busulfan-Cyclophosphamide Is Associated with Lower aGVHD and Higher Survival but More Extensive and Long Standing Bone Marrow Damage.氟达拉滨-白消安预处理与白消安-环磷酰胺预处理相比，急性移植物抗宿主病发生率更低、生存率更高，但骨髓损伤更广泛且持续时间更长。
Biomed Res Int. 2016;2016:3071214. doi: 10.1155/2016/3071214. Epub 2016 Oct 24.
5
A randomized clinical trial of a parent-focused social-cognitive processing intervention for caregivers of children undergoing hematopoetic stem cell transplantation.一项针对接受造血干细胞移植儿童的照料者的以家长为重点的社会认知加工干预的随机临床试验。
J Consult Clin Psychol. 2016 May;84(5):389-401. doi: 10.1037/ccp0000087. Epub 2016 Feb 25.
6
Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies.在采用减低剂量白消安/氟达拉滨预处理方案治疗血液系统恶性肿瘤后，使用移植后环磷酰胺预防移植物抗宿主病的II期试验
Biol Blood Marrow Transplant. 2015 May;21(5):906-12. doi: 10.1016/j.bbmt.2015.01.026. Epub 2015 Feb 7.
7
Preconditioning serum levels of endothelial cell-derived molecules and the risk of posttransplant complications in patients treated with allogeneic stem cell transplantation.异基因干细胞移植患者内皮细胞衍生分子的预处理血清水平与移植后并发症风险
J Transplant. 2014;2014:404096. doi: 10.1155/2014/404096. Epub 2014 Oct 8.
8
Results of a prospective multicentre myeloablative double-unit cord blood transplantation trial in adult patients with acute leukaemia and myelodysplasia.一项针对成年急性白血病和骨髓增生异常综合征患者的前瞻性多中心清髓性双单位脐血移植试验的结果。
Br J Haematol. 2015 Feb;168(3):405-12. doi: 10.1111/bjh.13136. Epub 2014 Oct 1.
9
Etanercept plus topical corticosteroids as initial therapy for grade one acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.依那西普联合外用糖皮质激素作为异基因造血细胞移植后1级急性移植物抗宿主病的初始治疗方法。
Biol Blood Marrow Transplant. 2014 Sep;20(9):1426-34. doi: 10.1016/j.bbmt.2014.05.023. Epub 2014 Jun 2.
10
Challenges and opportunities for international cooperative studies in pediatric hematopoeitic cell transplantation: priorities of the Westhafen Intercontinental Group.儿科造血细胞移植国际合作研究的挑战与机遇：威斯特法伦洲际组的优先事项。
Biol Blood Marrow Transplant. 2013 Sep;19(9):1279-87. doi: 10.1016/j.bbmt.2013.07.006. Epub 2013 Jul 21.
本文引用的文献
1
Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation.硼替佐米为基础的 HLA 不合无关供者移植移植物抗宿主病预防。
J Clin Oncol. 2012 Sep 10;30(26):3202-8. doi: 10.1200/JCO.2012.42.0984. Epub 2012 Aug 6.
2
Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation.比较供者移植物 CD34+ 选择与免疫抑制治疗作为完全缓解的急性髓细胞白血病患者 HLA 匹配同胞异基因造血细胞移植后移植物抗宿主病预防的疗效。
J Clin Oncol. 2012 Sep 10;30(26):3194-201. doi: 10.1200/JCO.2012.41.7071. Epub 2012 Aug 6.
3
Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease.阻断淋巴细胞趋化在肠道移植物抗宿主病中的作用。
N Engl J Med. 2012 Jul 12;367(2):135-45. doi: 10.1056/NEJMoa1201248.
4
Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium.NIH 综合皮肤评分、患者报告皮肤评分与结局的相关性：慢性移植物抗宿主病联盟研究结果。
Blood. 2012 Sep 27;120(13):2545-52; quiz 2774. doi: 10.1182/blood-2012-04-424135. Epub 2012 Jul 6.
5
Poor agreement between clinician response ratings and calculated response measures in patients with chronic graft-versus-host disease.慢性移植物抗宿主病患者的临床医生反应评分与计算反应测量之间的一致性较差。
Biol Blood Marrow Transplant. 2012 Nov;18(11):1649-55. doi: 10.1016/j.bbmt.2012.05.005. Epub 2012 Jun 9.
6
Clinical benefit of response in chronic graft-versus-host disease.慢性移植物抗宿主病反应的临床获益。
Biol Blood Marrow Transplant. 2012 Oct;18(10):1517-24. doi: 10.1016/j.bbmt.2012.05.016. Epub 2012 Jun 6.
7
Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study.治疗期间测量的急性移植物抗宿主病生物标志物可预测治疗结局：一项血液和骨髓移植临床试验网络研究。
Blood. 2012 Apr 19;119(16):3854-60. doi: 10.1182/blood-2012-01-403063. Epub 2012 Mar 1.
8
Design issues in randomized phase II/III trials.随机化 II/III 期临床试验中的设计问题。
J Clin Oncol. 2012 Feb 20;30(6):667-71. doi: 10.1200/JCO.2011.38.5732. Epub 2012 Jan 23.
9
Validation of measurement scales in ocular graft-versus-host disease.眼移植物抗宿主病测量量表的验证。
Ophthalmology. 2012 Mar;119(3):487-93. doi: 10.1016/j.ophtha.2011.08.040. Epub 2011 Dec 6.
10
Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria.根据 2005 年 NIH 共识标准的全球和器官特异性慢性移植物抗宿主病严重程度。
Blood. 2011 Oct 13;118(15):4242-9. doi: 10.1182/blood-2011-03-344390. Epub 2011 Jul 26.
Zotero 插件